The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Letters to the Editor

Published Online:https://doi.org/10.1176/ajp.155.11.1626w

To the Editor: We noted with interest the report by Sachdev et al. This retrospective study identified agitation, increased neuroleptic dosage, and history of ECT as risk factors for neuroleptic malignant syndrome. The clinical overlap of neuroleptic malignant syndrome and catatonia (1–3) prompts us to seek clarification related to catatonia.

The authors used catatonia as one of the possible subcriteria for diagnosis of neuroleptic malignant syndrome but did not report how many of the 25 patients or 50 comparison subjects showed catatonic signs. This is especially relevant since their definition of agitation as “excessive and purposeless motor activity” (p. 1156), which they found to be a risk factor for neuroleptic malignant syndrome, matches the published definitions for catatonic excitement (4, 5). DSM-IV and other diagnostic criteria (4) accept a single motor sign as sufficient to diagnose catatonia. The increased risk of neuroleptic malignant syndrome reported after administration of neuroleptics to patients with catatonia (1) may be confirmed if Sachdev et al. have data on catatonic signs in their neuroleptic malignant syndrome cases.

The authors also found prior history of ECT as a risk factor for neuroleptic malignant syndrome. Perhaps this also relates to catatonia, since this syndrome may be recurrent (6) and the patients with neuroleptic malignant syndrome may have had prior ECT, a common treatment for catatonia (7).

References

1. White DAC: Catatonia and the neuroleptic malignant syndrome-- a single entity? Br J Psychiatry 1992; 161:558–560Google Scholar

2. Goforth H, Carroll BT: The overlap of neuroleptic malignant syndrome (NMS) and catatonic diagnoses. J Neuropsychiatry Clin Neurosci 1995; 7:402Google Scholar

3. Fink M: Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry 1996; 39:1–4Google Scholar

4. Taylor MA: Catatonia—a review of a behavioral neurologic syndrome. Neuropsychiatry Neuropsychol Behav Neurol 1990; 3:48–72Google Scholar

5. Bush G, Fink M, Petrides G, Dowling F, Francis A: Catatonia I. Rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:137–143Crossref, MedlineGoogle Scholar

6. Francis A, Divadeenam K, Bush G, Petrides G: Consistency of symptoms in recurrent catatonia. Compr Psychiatry 1997; 38:56–60Crossref, MedlineGoogle Scholar

7. Francis A, Divadeenam K, Petrides G: Advances in diagnosis and treatment of catatonia. Convuls Ther 1996; 12:259–261MedlineGoogle Scholar